Clinical Significance of HER2 and EGFR Expression in Colorectal Cancer Patients with Ovarian Metastasis at a Tertiary Care Centre
DOI:
https://doi.org/10.21276/0my2wd53Keywords:
Colorectal Cancer, HER2, EGFR, PrognosisAbstract
Background: EGFR and HER2 overexpression has been reported to play important roles in colorectal cancer (CRC) development and metastasis. The purpose of the study is to compare the expression of HER2 and EGFR in primary tumours and ovarian metastases in CRC patients with ovarian metastases and their influence on prognosis.
Materials and Methods: The present study included 100 patients with CRC, Clinical examination, liver ultrasonography (US) or computed tomography (CT) scan were performed for each patient. The average age was 45.0 ± 12.0 years.
Results: There was no significant correlation in the expression of HER2 and EGFR with age, tumour site, tumour differentiation, tumour diameter, number of positive mesenteric lymph nodes or vascular cancer embolus (P > 0.05). There was no significant correlation between the expression of HER2 and the clinicopathological features in CRC patients with non-ovarian metastasis (P>0.05)
Conclusion: The present study revealed that HER2 and EGFR are highly expressed in ovarian metastases and primary tumours of CRC patients with ovarian metastases. Some preclinical and clinical studies have already demonstrated the efficacy of EGFR inhibitors in advanced colorectal carcinomas and their potential synergistic effects with chemotherapy and radiation therapy.
Downloads
References
Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of
colorectal cancer. Surgical Clinics. 2002 Oct 1;82(5):905-41.
Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonic
cancer. Histopathology. 1989 Jun;14(6):613-20.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature
reviews Molecular cell biology. 2001 Feb;2(2):127-37.
Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling
network: receptor heterodimerization in development and cancer. The
EMBO journal. 2000 Jul 3;19(13):3159-67.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M,
Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M. 2-year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast
cancer: a randomised controlled trial. The lancet. 2007 Jan
;369(9555):29-36.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use
of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar
;344(11):783-92.
Rego RL, Foster NR, Smyrk TC, Le M, O'connell MJ, Sargent DJ,
Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR
expression in human colon carcinomas: comparison with EGFR status.
British journal of cancer. 2010 Jan;102(1):165-72.
Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C,
Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A. EGFR FISH
assay predicts for response to cetuximab in chemotherapy refractory
colorectal cancer patients. Annals of Oncology. 2008 Apr 1;19(4):717-23.
Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S,
Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S. Prognostic and
predictive value of HER2 amplification in patients with metastatic
colorectal cancer. Clinical colorectal cancer. 2018 Sep 1;17(3):198-205.
Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, PenaultLlorca F, Van De Vijver M, Viale G. HER2 testing in gastric cancer: a
practical approach. Modern Pathology. 2012 May;25(5):637-50.
Lee WS, Baek JH, Lee JN, Lee WK. Mutations in K-ras and epidermal
growth factor receptor expression in Korean patients with stages III and
IV colorectal cancer. International journal of surgical pathology. 2011
Apr;19(2):145-51.
Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic
value of coexpressed erbB family members for the survival of colorectal
cancer patients after curative surgery. European Journal of Cancer. 2002
May 1;38(8):1065-71.
McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J. Cyclin
D1 protein expression and gene polymorphism in colorectal cancer.
International journal of cancer. 2000 Oct 1;88(1):77-81.
Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar
A, Benichou J, Martin A, Morere JF, Raphael M. Impact of EGFR
expression on colorectal cancer patient prognosis and survival. Annals of
oncology. 2005 Jan 1;16(1):102-8.
Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI,
Han WK, Kim H, Ryu SH. HER-2/neu overexpression is an independent
prognostic factor in colorectal cancer. International journal of colorectal
disease. 2007 May;22(5):491-7.
Antonacopoulou AG, Tsamandas AC, Petsas T, Liava A, Scopa CD,
Papavassiliou AG, Kalofonos HP. EGFR, HER-2 and COX-2 levels in
colorectal cancer. Histopathology. 2008 Dec;53(6):698-706.
Demirbaş S, Sücüllü I, YILDIRIM Ş, Celenk T. Influence of the c-erb B-2,
nm23, bcl-2 and p53 protein markers on colorectal cancer. Turkish
Journal of Gastroenterology. 2006;17(1):13-9.
Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski
M, Jasiński W, Kawecki K, Wojtacki J. Expression of HER2 in colorectal
cancer does not correlate with prognosis. Disease markers. 2010 Jan
;29(5):207-12.
Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani
F, Eustace PW, Tobbia I. Is overexpression of HER-2 a predictor of
prognosis in colorectal cancer?. BMC cancer. 2009 Dec;9(1):1-6.
Kim JY, Lim SJ, Park K. Cyclooxygenase-2 and c-erbB-2 expression in
colorectal carcinoma assessed using tissue microarrays. Applied
Immunohistochemistry & Molecular Morphology. 2004 Mar 1;12(1):67-70.
Missiaglia E, Jacobs B, D'ario G, Di Narzo AF, Soneson C, Budinska E,
Popovici V, Vecchione L, Gerster S, Yan P, Roth AD. Distal and proximal
colon cancers differ in terms of molecular, pathological, and clinical
features. Annals of oncology. 2014 Oct 1;25(10):1995-2001.
Heppner BI, Behrens HM, Balschun K, Haag J, Krüger S, Becker T,
Röcken C. HER2/neu testing in primary colorectal carcinoma. British
journal of cancer. 2014 Nov;111(10):1977-84.
Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast
cancer: are we there yet?. Pathology Patterns Reviews. 2004 May
;121(suppl_1):S33-49.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ,
Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD. Wild-type KRAS
is required for panitumumab efficacy in patients with metastatic colorectal
cancer. J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi:
1200/JCO.2007.14.7116. Epub 2008 Mar 3.
Feng Q, Pei W, Zheng ZX, Bi JJ, Yuan XH. Clinicopathologic
characteristics and prognostic factors of 63 gastric cancer patients with
metachronous ovarian metastasis. Cancer biology & medicine. 2013
Jun;10(2):86.
Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De
Dosso S, Spitale A, Tejpar S, Kalogeras KT. HER2 gene copy number
status may influence clinical efficacy to anti-EGFR monoclonal antibodies
in metastatic colorectal cancer patients. British journal of cancer. 2013
Feb;108(3):668-75.
Bibeau F, Boissière-Michot F, Sabourin JC, Gourgou-Bourgade S, Radal
M, Penault-Llorca F, Rochaix P, Arnould L, Bralet MP, Azria D, Ychou M.
Assessment of epidermal growth factor receptor (EGFR) expression in
primary colorectal carcinomas and their related metastases on tissue
sections and tissue microarray. Virchows Archiv. 2006 Sep;449(3):281-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
